Compare LEA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEA | BLTE |
|---|---|---|
| Founded | 1917 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.0B |
| IPO Year | 1994 | 2021 |
| Metric | LEA | BLTE |
|---|---|---|
| Price | $142.71 | $160.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $132.21 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 535.3K | 192.7K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $23,259,100,000.00 | N/A |
| Revenue This Year | $2.50 | N/A |
| Revenue Next Year | $3.12 | $492.11 |
| P/E Ratio | $41.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $91.67 | $60.00 |
| 52 Week High | $150.33 | $200.00 |
| Indicator | LEA | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 59.27 | 61.82 |
| Support Level | $139.14 | $146.18 |
| Resistance Level | $149.68 | $172.02 |
| Average True Range (ATR) | 3.54 | 7.27 |
| MACD | 1.08 | 0.65 |
| Stochastic Oscillator | 90.66 | 97.97 |
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.